Phase I bioequivalence study of controlled-release pregabalin 165mg once daily versus pregabalin 75mg twice daily
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2014
At a glance
- Drugs Pregabalin (Primary)
- Indications Diabetic neuropathies; Fibromyalgia; Neuropathic pain
- Focus Pharmacokinetics
- 14 Nov 2014 New trial record
- 22 Oct 2014 Primary endpoint (Pharmacokinetic parameters: AUC and Cmax) has been met, according to an Intellipharmaceutics media release.
- 22 Oct 2014 Results published in Intellipharmaceutics media release.